Royalty Pharma plc

RPRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $812.0M $586.4M $618.7M $938.9M $631.9M $1.09B $929.0M $950.1M
Accounts Receivable
Inventory
Total Current Assets $1.76B $1.43B $1.53B $1.85B $1.52B $1.84B $1.80B $1.79B
Property, Plant & Equipment
Goodwill $923.5M $924.6M $924.6M $924.6M $924.6M $0
Intangible Assets (Excl. Goodwill)
Total Assets $19.82B $19.82B $19.62B $19.35B $18.32B $17.61B $18.22B $18.04B
Liabilities
Accounts Payable
Total Current Liabilities $630.9M $535.7M $636.2M $530.8M $1.21B $1.18B $1.25B $1.17B
Long-Term Debt $8.58B $8.58B $8.57B $8.57B $7.00B $6.62B $6.61B $6.61B
Total Liabilities $10.03B $9.88B $9.91B $9.73B $8.82B $7.82B $7.88B $7.78B
Stockholders' Equity
Retained Earnings $2.46B $2.51B $2.36B $2.30B $2.22B $2.48B $2.85B $2.76B
Total Stockholders' Equity $9.79B $9.94B $9.71B $9.62B $9.49B $9.78B $10.34B $10.26B
← Newer Page 1 of 4 Older →